Anti-netrin-1 antibody

A method of treating cancer in a subject having a cancer expressing both netrin-1 and a netrin-1 receptor comprising:

• administering to said subject a therapeutically effective amount of a netrin-1 binding monoclonal antibody or antigen-binding fragment thereof, wherein said monoclonal antibody or antigen-binding fragment thereof each comprises:
• (i) a Variable Heavy (VH) chain comprising a CDR1-H having SEQ ID NO:
• 28, a CDR2-H having SEQ ID NO:
• 29 and a CDR3-H having SEQ ID NO:
• 30;
• and
• (ii) a Variable Light (VL) chain comprising a CDR1-L having SEQ ID NO:
• 31, a CDR2-L having SEQ ID NO:
• 32 and a CDR3-L having SEQ ID NO:
• 9,
• wherein said monoclonal antibody or antigen-binding fragment thereof each comprises VH and VL polypeptides which each are at least 85% identical respectively to the VH polypeptide of SEQ ID NO:
• 20 and the VL polypeptide of SEQ ID NO:
• 14;
• to the VH polypeptide of SEQ ID NO:
• 21 and the VL polypeptide of SEQ ID NO:
• 15;
• to the VH polypeptide of SEQ ID NO:
• 22 and the VL polypeptide of SEQ ID NO:
• 16;
• to the VH polypeptide of SEQ ID NO:
• 23 and the VL polypeptide of SEQ ID NO:
• 17;
• to the VH polypeptide of SEQ ID NO:
• 24 and the VL polypeptide of SEQ ID NO:
• 17;
• to the VH polypeptide of SEQ ID NO:
• 25 and the VL polypeptide of SEQ ID NO:
• 16;
• to the VH polypeptide of SEQ ID NO:
• 26 and the VL polypeptide of SEQ ID NO:
• 17;
• to the VH polypeptide of SEQ ID NO:
• 22 and the VL polypeptide of SEQ ID NO:
• 17;
• to the VH polypeptide of SEQ ID NO:
• 25 and the VL polypeptide of SEQ ID NO:
• 18;
• or to the VH polypeptide of SEQ ID NO:
• 21 and the VL polypeptide of SEQ ID NO:
• 16.